Compare

Medacta Group SA/Fr. MOVE

1D1W1M3M6MYTD1Y5YMAX

About Medacta Group SA

Medacta Group SA is a Swiss-based company specializing in the design, production, and distribution of orthopedic medical devices. The company's core business focuses on hip and knee replacement products, as well as spine surgery and sports medicine solutions. Founded in 1999, Medacta is headquartered in Castel San Pietro, Switzerland. The company distinguishes itself through its commitment to medical education, providing training and resources to healthcare professionals to enhance surgical outcomes. Medacta also emphasizes innovation in minimally invasive surgical techniques and personalized solutions to improve patient care and recovery times.
Ticker
Fr. MOVE
Sector
Health
Primary listing
XSWX
Employees
2,273
Headquarters
Castel San Pietro, Switzerland
Website
www.medacta.com

Medacta Group SA Metrics

BasicAdvanced
CHF 2.3B
33.06
CHF 3.56
0.97
CHF 1.10
0.47%

What the Analysts think about Medacta Group SA

Analyst ratings (Buy, Hold, Sell) for Medacta Group SA stock.
Analyst projections of the future price of Medacta Group SA stock.

Bulls say / Bears say

H1 2026 revenue rose 9.7% in constant currency to €368 million, and management kept its 10–14% full-year growth and 12–15% mid-term growth targets. That points to continued expansion, provided the company delivers on its guidance. (Medacta Corporate)
Growth is not resting on one product line: knee revenue rose 10.8% and Extremities revenue 15.9% in constant currency in H1. Continued surgeon adoption of its knee platform and strength in shoulder and sports medicine give Medacta several avenues for growth. (Medacta Corporate, EQS News)
Medacta has begun limited-market use of NextAR Hip in the US and Australia, following its first clinical cases. If surgeons adopt the system more widely, it could extend the company’s technology offering and support future sales. (Medacta Corporate)
Profitability weakened in H1: gross margin fell to 65.2% from 68.3%, while the adjusted EBITDA margin in euros dropped to 26.5% from 28.7%. Foreign exchange, product and regional mix, price erosion and higher depreciation are weighing on margins. (Medacta Corporate)
Cash generation was weak: operating cash flow fell to €55.7 million from €73 million, and free cash flow turned negative at €18.6 million. Higher inventory and substantial investment spending could keep cash conversion under pressure as the company expands. (Investing.com)
North American growth was only 6.6% in constant currency in H1, with softer activity among existing joint customers and a US spine sales-channel transition holding back performance. Continued weakness there could make it harder to meet group growth targets. (Medacta Corporate)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.

Medacta Group SA Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Medacta Group SA Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Medacta Group SA

AllUSDEURGBP
Funds
Fund name
Fund size
Fr. MOVE weighting
iShares Ageing Population$AGED
$953M0.08%
iShares Ageing Population€AGED
$903M0.08%
iShares Ageing Population£AGES
$953M0.08%
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.05%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.05%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.